SPI.L

Spire Healthcare Group Plc
Spire Healthcare Grp - Total Voting Rights and Capital
1st July 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 4121T
Spire Healthcare Group PLC
01 July 2024
 

Spire Healthcare Group plc

Total Voting Rights and Capital

1 July 2024

In accordance with DTR 5.6 of the FCA's Disclosure and Transparency Rules, Spire Healthcare Group plc (the 'Company') advises that 2,130 ordinary shares of 1p each with voting rights were issued during June 2024.

As at 30 June 2024 the Company's issued share capital consisted of 404,134,364 ordinary shares of 1p each with voting rights. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules. The Company does not hold any shares in Treasury at the date of this disclosure.

For further information contact:

Angus Prentice - Director of Investor Relations

+44 (0)20 7427 9000

Notes:

LEI: 213800IBJPW3SE2RA350

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRUAOKRSRUNURR]]>
TwitterFacebookLinkedIn